The average one-year price target for Atossa Therapeutics (NasdaqCM:ATOS) has been revised to $23.46 / share. This is a ...
Atossa Therapeutics (NASDAQ:ATOS) added ~17% to rise sharply for the second straight session on Wednesday after announcing that enrollment in a mid-stage trial for its experimental breast cancer ...
Stocktwits on MSN
Atossa Therapeutics stock jumps after FDA grants rare pediatric status to DMD drug — retail bets on phase 3 fast-track
The FDA designation expands Atossa’s investigational therapy into rare pediatric neuromuscular disease. ・The program could become eligible for a Priority Review Voucher upon future approval.
The MarketWatch News Department was not involved in the creation of this content. Recognized for Visionary Leadership and Advancing Innovative Therapies in Oncology and Healthcare Technology SEATTLE, ...
What To Know: The FDA granted one of the biopharmaceutical company’s potential treatments, (Z)-Endoxifen, a rare pediatric disease designation for the treatment of Duchenne Muscular Dystrophy. The ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atossa Genetics Inc. (ATOS) one of those stocks right now? Let ...
Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results